QUEBEC, Jan. 7 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., "Victhom" (TSX: VHB), announced today that it will participate in the OneMedPlace Finance Forum in San Francisco, CA on January 13 and 14, 2009. Nader Kameli, Chief Operating Officer of Victhom's Neurobionix division, will be presenting on Tuesday, January 13 at 9:00 a.m. Pacific Time, at the Sir Francis Drake Hotel at 450 Powell Street. Information about the OneMedPlace Finance Forum may be found at http://www.onemedplace.com.
Victhom has developed the Neurostep(R) System, an implantable neurostimulation device designed to restore mobility and independence for patients with partial paralysis of the leg as a result of hemiparetic stroke. The Neurostep(R) System has been engineered to integrate with the body's natural sensing and stimulation network and designed to closely mimic specific functions that have been interrupted or lost due to disease or injury. The Neurostep(R) is an investigational medical device currently in human clinical study in four clinical sites outside U.S. and is planned for market introduction in Europe late 2009.
Victhom discovers, develops and manufactures bionic devices involved in the treatment of a variety of physical and physiological dysfunctions. Victhom's Neurobionix division focuses on the development and commercialization of technologies and products involving implantable devices that feature neurosensing and neurostimulation components, integrated with artificial intelligence. Victhom's Biotronix division develops biomechatronic products to support or replace peripheral limbs in what is known as the orthotics and prosthetics market.
OneMedPlace is a virtual community of healthcare and life science companies. It has, for the first time, put in place the innovations that will shape the future of health and medicine emerging companies and technologies seeking capital, distribution, visibility and resources to help finance, build and grow, and investors and strategic partners looking for health and medical innovations to invest in, acquire, license, distribute, purchase or utilize.
Some of the statements made herein may constitute forward-looking statements. These statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause Victhom's actual results, performance or achievements to be materially different from those expressed or implied by any of Victhom's statements. Actual events or results may differ materially. We disclaim any intention, and assume no obligation, to update these forward-looking statements.
|SOURCE VICTHOM HUMAN BIONICS INC.|
Copyright©2009 PR Newswire.
All rights reserved